



ASX & Media Release

December 2018 Appendix 4C

Melbourne, Australia; 30 January, 2019: Patrys Limited (**ASX: PAB**) is pleased to lodge its Appendix 4C for the quarter ended 31 December 2018.

FINANCE

At the end of December the Company held cash reserves of \$6,077,000 with a further \$2,000,000 on deposit with maturity greater than 3 months. Net cash inflows from operating activities during the quarter were \$2,403,000. Operating costs for the quarter were \$1,247,000, and revenues of \$3,650,000 consisted of a \$3 million settlement of insurance claims related the failed manufacture campaign of PAT-SM6, government grants and tax incentive refunds of \$606,000 and other revenues.

Cash outflows in the quarter ended 31 December 2018, were \$150,000 more than forecast for the quarter, mainly due to payments related to the insurance settlement.

OPERATIONS

Patrys continues to progress its PAT-DX1 asset, building a strong position in the field of DNA damage repair (DDR) therapeutics.

On 22nd November 2018 the Company's CEO Dr James Campbell presented at the Annual General Meeting and outlined progress on operational activities in the last 12 months. The CEO's presentation outlined planned activities for 2019, including a number of animal models, development of PAT-DX1 manufacturing, new intellectual patent grants and a focus on establishment on collaborations and alliances.

On 20th December 2018 the Company announced further pre-clinical data in a Triple Negative Brain Cancer (TNBC) metastasis model. Brain metastases were generated by injection of luciferase-labelled, brain-seeking TNBC cells directly into circulation via intracardiac injection. One week later, the presence of brain metastases was confirmed and intravenous treatment with PAT-DX1 was initiated. The ability of PAT-DX1 to reduce TNBC brain metastasis was seen after just one week of treatment. After 4 weeks of treatment with PAT-DX1, treated mice showed 93% less brain metastasis than untreated mice, quantified by luminescence intensity. PAT-DX1 also significantly improved survival, with 86% of the mice treated with PAT-DX1 still alive after all control mice had died. No toxicity associated with PAT-DX1 treatment was observed. This positive result will be expanded upon by the Company in 2019.

Subsequent events

On 8th January 2019 the Company announced that its CEO, Dr James Campbell would present the company and its technologies at the Biotech Showcase™ Annual Conference in San Francisco on Tuesday 8th January, 2019 at the Hilton San Francisco Union Square. The Biotech Showcase™ is devoted to biotechnology companies and coincides with the 37th Annual JP Morgan Healthcare Conference and associated life sciences investment and partnering meetings. The Biotech Showcase™ attracts over 3,600 attendees, including 400 presenting companies and over 900 investors. On the 9th January 2019 the Company posted the presentation for shareholders to view.



An Appendix 4C accompanies this announcement.

For and on behalf of the Board of Patrys Limited,

Melanie Leydin
CFO and Company Secretary

About Patrys Limited:

Based in Melbourne, Australia, Patrys (ASX: PAB) is focused on the development of antibodies as therapies for a range of different cancers. Patrys has a pipeline of anti-cancer antibodies for both internal development and as partnering opportunities. More information can be found at www.patrys.com.

Appendix 4C

Quarterly report for entities subject to Listing Rule 4.7B

Introduced 31/03/00 Amended 30/09/01, 24/10/05, 17/12/10, 01/09/16

Name of entity

Patrys Limited

ABN

97 123 055 363

Quarter ended ("current quarter")

31 DECEMBER 2018

Consolidated statement of cash flows	Current quarter \$A'000	Year to date (6 months) \$A'000
1. Cash flows from operating activities		
1.1 Receipts from customers	27	27
1.2 Payments for		
(a) research and development	(401)	(777)
(b) product manufacturing and operating costs	-	-
(c) advertising and marketing	-	-
(d) leased assets	-	-
(e) staff costs	(163)	(342)
(f) administration and corporate costs	(615)	(938)
1.3 Dividends received (see note 3)	-	-
1.4 Interest received	17	24
1.5 Interest and other costs of finance paid	-	-
1.6 Income taxes paid	-	-
1.7 Government grants and tax incentives	606	606
1.8 Other		
- IP expenditure	(68)	(139)
- Insurance Settlement	3,000	3,000
1.9 Net cash from / (used in) operating activities	2,403	1,461

2. Cash flows from investing activities		
2.1 Payments to acquire:		
(a) property, plant and equipment	-	-
(b) businesses (see item 10)	-	-

Consolidated statement of cash flows	Current quarter \$A'000	Year to date (6 months) \$A'000
(c) investments	-	-
(d) intellectual property	-	-
(e) other non-current assets	-	-
2.2 Proceeds from disposal of:		
(a) property, plant and equipment	-	-
(b) businesses (see item 10)	-	-
(c) investments	-	-
(d) intellectual property	-	-
(e) other non-current assets	-	-
2.3 Cash flows from loans to other entities	-	-
2.4 Dividends received (see note 3)	-	-
2.5 Other (cash on deposits)	-	-
2.6 Net cash from / (used in) investing activities	-	-

3. Cash flows from financing activities		
3.1 Proceeds from issues of shares	-	2
3.2 Proceeds from issue of convertible notes	-	-
3.3 Proceeds from exercise of share options	-	-
3.4 Transaction costs related to issues of shares, convertible notes or options	-	-
3.5 Proceeds from borrowings	-	-
3.6 Repayment of borrowings	-	-
3.7 Transaction costs related to loans and borrowings	-	-
3.8 Dividends paid	-	-
3.9 Other (provide details if material)	-	-
3.10 Net cash from / (used in) financing activities	-	2

4. Net increase / (decrease) in cash and cash equivalents for the period		
4.1 Cash and cash equivalents at beginning of quarter/year to date	3,670	4,605
4.2 Net cash from / (used in) operating activities (item 1.9 above)	2,403	1,461
4.3 Net cash from / (used in) investing activities (item 2.6 above)	-	-
4.4 Net cash from / (used in) financing activities (item 3.10 above)	-	2

Consolidated statement of cash flows		Current quarter \$A'000	Year to date (6 months) \$A'000
4.5	Effect of movement in exchange rates on cash held	4	9
4.6	Cash and cash equivalents at end of quarter ¹	6,077	6,077

¹ The cash balance above excludes \$2 million of cash on deposit with a maturity date greater than 3 months.

5.	Reconciliation of cash and cash equivalents at the end of the quarter (as shown in the consolidated statement of cash flows) to the related items in the accounts	Current quarter \$A'000	Previous quarter \$A'000
5.1	Bank balances	4,065	1,670
5.2	Call deposits	2,012	2,000
5.3	Bank overdrafts	-	-
5.4	Other	-	-
5.5	Cash and cash equivalents at end of quarter (should equal item 4.6 above) ¹	6,077	3,670

¹ The cash balance for the current quarter and previous quarter excludes \$2 million of cash on deposit with a maturity date greater than 3 months.

6.	Payments to directors of the entity and their associates	Current quarter \$A'000
6.1	Aggregate amount of payments to these parties included in item 1.2	127
6.2	Aggregate amount of cash flow from loans to these parties included in item 2.3	-
6.3	Include below any explanation necessary to understand the transactions included in items 6.1 and 6.2	

Cash payments to directors for executive director salaries, non-executive director fees and consulting services for the quarter.

7.	Payments to related entities of the entity and their associates	Current quarter \$A'000
7.1	Aggregate amount of payments to these parties included in item 1.2	-
7.2	Aggregate amount of cash flow from loans to these parties included in item 2.3	-
7.3	Include below any explanation necessary to understand the transactions included in items 7.1 and 7.2	

-

8. Financing facilities available <i>Add notes as necessary for an understanding of the position</i>	Total facility amount at quarter end \$A'000	Amount drawn at quarter end \$A'000
8.1 Loan facilities	-	-
8.2 Credit standby arrangements	-	-
8.3 Other (please specify)	-	-
8.4 Include below a description of each facility above, including the lender, interest rate and whether it is secured or unsecured. If any additional facilities have been entered into or are proposed to be entered into after quarter end, include details of those facilities as well.		


-

9. Estimated cash outflows for next quarter	\$A'000
9.1 Research and development	661
9.2 Product manufacturing and operating costs	-
9.3 Advertising and marketing	-
9.4 Leased assets	-
9.5 Staff costs	130
9.6 Administration and corporate costs	344
9.7 Other (provide details if material) (IP)	43
9.8 Total estimated cash outflows	1,178

10. Acquisitions and disposals of business entities (items 2.1(b) and 2.2(b) above)	Acquisitions	Disposals
10.1 Name of entity	-	-
10.2 Place of incorporation or registration	-	-
10.3 Consideration for acquisition or disposal	-	-
10.4 Total net assets	-	-
10.5 Nature of business	-	-

Compliance statement

- 1 This statement has been prepared in accordance with accounting standards and policies which comply with Listing Rule 19.11A.
- 2 This statement gives a true and fair view of the matters disclosed.

Sign here: 
(Company secretary)

Date: 30 January 2019

Print name: Melanie Leydin

Notes

1. The quarterly report provides a basis for informing the market how the entity's activities have been financed for the past quarter and the effect on its cash position. An entity that wishes to disclose additional information is encouraged to do so, in a note or notes included in or attached to this report.
2. If this quarterly report has been prepared in accordance with Australian Accounting Standards, the definitions in, and provisions of, *AASB 107: Statement of Cash Flows* apply to this report. If this quarterly report has been prepared in accordance with other accounting standards agreed by ASX pursuant to Listing Rule 19.11A, the corresponding equivalent standard applies to this report.
3. Dividends received may be classified either as cash flows from operating activities or cash flows from investing activities, depending on the accounting policy of the entity.